Patents (FY 2008-2011)
Inventions made by NCTT employees are owned by the federal government. Patenting and licensing are used to help ensure the technology is fully developed, commercialized and advancing public health. Please see the list of our lead inventors below and links to their active patents/patent Applications.
All technology and partnership inquiries can be directed to NCTT Technology Transfer Staff:
Phone: (301) 217-4679
E-mail: NCTTPartnerships@nih.gov
Please Note: The Abstract Details below are provided by the NIH Office of Technology Transfer.
Boxer, Matthew (NCTT)
Substituted 3-Oxo-3, 4-Dihydroquinoline-2H-Benzo [B] [1,4] Oxazine-7-Sulfonamides and 2-Oxo-1,2,3,4-Tetrahydroquinoline-6-Sulfonamides Small Molecule Activators of Human Pyruvate Kinase
Additional Inventors: Auld, Douglas (NCTT), Shen, Min (NCTT), Thomas, Craig (NCTT)
Abstract: NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics. (Abstract Details)
Maloney, David (NCTT)
Discovery of Potent and Selective Inhibitors Of 15-1 Human Lipoxygenase
Additional Inventors: Jadhav, Ajit P. (NCTT), Simeonov, Anton M. (NCTT), Bantukallu, Ganesha R. (NCTT), Kenyon, Victor (UCSC) Holman, Theodore (UCSC)
WIPO Pub. No.: WO/2011/028651
Discovery of Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Prevention of Platelet-Mediated Clot Formation Caused by Cardiovascular Disease
Additional Inventors: Bantukallu, Ganesha (NCTT), Holinstat, Michael (Thomas Jefferson University), Holman, Theodore (University of California, San Diego), Jadhav, Ajit (NCTT), Kenyon, Victor (University of California, San Diego)
Abstract: This invention discloses small molecule inhibitors of human 12-lipoxygenase (12-hLO). 12-lipoxygenase expression, activation, and lipid metabolites have been implicated in type 1 and type 2 diabetes, cardiovascular disease, hypertension, Alzheimer’s, and Parkinson’s disease. (Abstract Details)
Marugan, Juan (NCTT)
Arylthiazol yl Piperidines and Related Compounds as Modulators of Survival Motor neuron (SMN) Protein Production
Additional Inventors: Androphy, Elliot J. (U of Mass. Med. School), Cherry, Jonathan (U of Mass. Med. School), Southall, Noel (NCTT) Titus, Steven (NCTT), Xiao, Jingbo (NCTT), Zheng, Wei (NCTT)
Abstract: This technology discloses compounds that modulate the amount of Survival Motor Neuron protein (SMN). Low levels of SMN protein are associated with Spinal Muscular Atrophy (SMA), which constitutes a group of inherited diseases that cause progressive muscle degeneration leading to death. Consequently, therapeutic inventions have focused on increasing SMN protein levels. This invention discloses novel arylthiazolyl piperidines which are shown to be modulators of SMN production. This invention also discloses methods of treating SMA by administering SMN protein modulators. (Abstract Details)
Delivery of a Therapeutic Protein, Transthyretin (TTR), across the Blood-Brain Barrier (BBB) as a Treatment for Alzheimer's Disease
Additional Inventors: Zheng, Wei (NCTT), Muro-Galindo, Silvia (University of Maryland Biotechnology Institute)
Abstract: The invention describes products and methods of treating Alzheimer's disease. Alzheimer's disease is characterized by the formation of amyloid plaques and tangles in areas of the brain critical for learning and memory. (Abstract Details)
Glucocerebrosidase Activators as a Treatment for Gaucher Disease
Additional Inventors: Goldin, Ehud (NHGRI), Motabar, Omid (NHGRI), Patnaik, Samarjit (NCTT), Sidransky, Ellen (NHGRI), Southall, Noel (NCTT), Westbroek, Wendy (NHGRI), Zheng, Wei (NCTT)
Abstract: This technology is a collection of small molecule activators of a genetically defective version of the enzyme called glucocerebrosidase (GCase), which causes Gaucher disease. (Abstract Details)
Novel Thio-Ether Analogues as a Treatment for Huntington's Disease
Additional Inventors: Goldin, Ehud (NHGRI), Motabar, Omid (NHGRI), Patnaik, Samarjit (NCTT), Sidransky, Ellen (NHGRI), Southall, Noel (NCTT), Westbroek, Wendy (NHGRI), Zheng, Wei (NCTT)
Abstract: This technology is a collection of small molecules screened for their ability to prevent or reduce the cytotoxic effects of the protein, Huntingtin. Huntington's disease is a neurodegenerative disorder due to a dominantly acting expansion of a CAG trinucleotide repeat in exon 1 of the Huntington (HTT) gene resulting in production of the altered (mutant) protein Huntingtin, which has a long chain of polyglutamine (poly Q) attached to the exon 1 encoded protein sequence. (Abstract Details)
Small Molecule Neuropeptide S (NPS) Antagonists for the Treatment of Addictive Disorders, Mood and Anxiety Disorders and Sleep Disorders
Additional Inventors: Heilig, Markus (NIAAA), Liu, Ke (NHGRI), Patnaik, Samarjit (NCTT), Southall, Noel (NCTT), Zheng, Wei (NCTT)
Abstract: The inventors, who work for the National Human Genome Research Institute (NHGRI) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health (NIH), have developed NPSR antagonists that hold the potential for being clinically useful treatments for alcohol and drug addiction. (Abstract Details)
Thomas, Craig (NCTT)
Caspase 1 Inhibitor
Additional Inventors: Boxer, Matthew (NCTT)
Abstract: Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. (Abstract Details)
Substituted 3,6-Diphenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]Thiadiazines as Potent Inhibitors of PDE4A, PDE4B And PDE4D
Additional Inventors: Leclair, Christopher (NCTT), Skoumbourdis, Amanda (NCTT), Xia, Menghang (NCTT)
WIPO Pub. No.: WO/2009/089027
Substituted Oxadiazole 2-oxides As A Treatment Of Schistosomiasis
Additional Inventors: Bantukallu, Ganesha (NCTT), Maloney, David (NCTT), Sayed, Ahmed (llinois State Univ.), Simeonov, Anton (NCTT), Williams, David (Illinois State Univ.)
Abstract: Available for licensing and commercial development are pharmaceutical compositions and methods for the treatment of Schistosomiasis in mammals. The various compositions are based on a number of compounds derived from 1,2,5-oxadiazole that are potent inhibitors of thioredoxin glutathione reductase (TGR), a critical parasite redox protein. (Abstract Details)
WIPO Pub. No.: WO/2010/019772
Substituted Triazincs As Inhibitors Of Cruzain And Rhodesain And As Front Line Therapies For Chagas' Disease And African Trypanosomiasis
Additional Inventors: Jadhav, Ajit (NCTT), Maloney, David (NCTT), Mott, Bryan (NCTT), Simeonov, Anton (NCTT)
WIPO Pub. No.: WO/2010/059418
Small Molecule Activators Of Human Pyruvate Kinase
Additional Inventors: Auld, Douglas (NCTT), Boxer, Matthew (NCTT), Inglese, James (NCTT), Jiang, Jian-kang (NCTT), Skoumbourdis, Amanda (NCTT)
Abstract: NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics. (Abstract Details)
WIPO Pub. No.: WO/2010/042867
WIPO: World Intellectual Property Organization
Last Updated: August 29, 2011
